Anti-angiogenesis medications, including TKIs and mono-antibodies, target vascular endothelial growth factor (VEGF) signaling, normalize tumor blood vessels, regulate the tumor microenvironment, and enhance the efficacy of ICIs (6, 7). The gene discussed is VEGFA; the disease is neoplasm.